ONCAlert | Upfront Therapy for mRCC

Evaluating the Role of Ruxolitinib as Treatment of Graft-Versus-Host Disease

Tania Jain, MBBS
Published Online: 11:26 PM, Wed February 19, 2020


Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses the role of ruxolitinib (Jakafi) as treatment of graft-versus-host disease (GVHD).

At her institution, she has used ruxolitinib as treatment of GVHD for patients with grade 2 through 4 disease. However, because of the biology of GVHD, responses are observed more frequently in patients with grade 2 versus grades 3 and 4 GVHD. This is consistent with data that has been observed in the REACH-1 and REACH-2 clinical trials.

Although there are responses with ruxolitinib, physicians should be wary of potential infections or cytopenias, Jain says. Physicians should keep these concerns in mind as they use the agent.

<< View more from the 2020 TCT Meetings

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.